Press release, Helsinki, 2 July 2025 at 9 AM (EEST) 

Nexstim Receives NBS System 6 Order from US Customer

Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS 6 system from an existing customer in the United States. The customer is an experienced user of the Nexstim therapy system that is now upgrading their device.

The NBS 6 is a new generation Nexstim system that makes the Company’s clinically established, e-field navigated TMS (transcranial magnetic stimulation) technology more user-friendly than ever before.  The NBS 6 system is currently CE-marked for the treatment of major depression and chronic neuropathic pain in the EU, and FDA-cleared for the treatment of major depressive disorder (MDD) in the United States.

Mikko Karvinen, CEO of Nexstim, comments: “This order came from a customer that has successfully treated patients with our earlier generation therapy system for a long time. We are now very happy about them continuing their active Nexstim use with a new NBS 6 system treating MDD as well as for training purposes.”

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO

+358 50 326 4101

mikko.karvinen@nexstim.com

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.

Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit www.nexstim.com

AttachmentsNexstim Plc_Press release_US order_02072025_FINAL.pdf